These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 11807995)

  • 1. John McCamant on the future of biotech. Interview by Dennis Murray.
    McCamant J
    Med Econ; 2002 Jan; 79(1):43-6. PubMed ID: 11807995
    [No Abstract]   [Full Text] [Related]  

  • 2. US government previews biotech survey.
    Goho A
    Nat Biotechnol; 2003 Aug; 21(8):837-8. PubMed ID: 12894185
    [No Abstract]   [Full Text] [Related]  

  • 3. Hedge funds gain edge by doubling biotech investments.
    Ransom J
    Nat Biotechnol; 2006 Apr; 24(4):373-4. PubMed ID: 16601707
    [No Abstract]   [Full Text] [Related]  

  • 4. Biotech holds its own in Q2.
    Lawrence S
    Nat Biotechnol; 2004 Aug; 22(8):938. PubMed ID: 15286634
    [No Abstract]   [Full Text] [Related]  

  • 5. Is your biotech giving away the store?
    Jacobs T
    Nat Biotechnol; 2002 Nov; 20(11):1079. PubMed ID: 12410245
    [No Abstract]   [Full Text] [Related]  

  • 6. Crystal gazing: biotech's financial outlook: the biotech analyst's view.
    Schmidt E
    Nat Biotechnol; 2006 Mar; 24(3):261-2. PubMed ID: 16525376
    [No Abstract]   [Full Text] [Related]  

  • 7. White biotech and the financial crisis.
    Rabinovich M
    Biotechnol J; 2009 Aug; 4(8):1117-23. PubMed ID: 19685465
    [No Abstract]   [Full Text] [Related]  

  • 8. Biotech holds steady in Q4.
    Mitchell P
    Nat Biotechnol; 2004 Feb; 22(2):135-6. PubMed ID: 14755275
    [No Abstract]   [Full Text] [Related]  

  • 9. Icelandic biotech feels the pinch.
    Wadman M
    Nature; 2008 Oct; 455(7215):842. PubMed ID: 18938257
    [No Abstract]   [Full Text] [Related]  

  • 10. Biotech IPOs--flop or pop?
    Jacobs T
    Nat Biotechnol; 2004 Aug; 22(8):949. PubMed ID: 15286641
    [No Abstract]   [Full Text] [Related]  

  • 11. Biotech financing retrenches in Q2.
    Lawrence S
    Nat Biotechnol; 2006 Aug; 24(8):883. PubMed ID: 16900116
    [No Abstract]   [Full Text] [Related]  

  • 12. Chasing biotech, state by state--winners and losers.
    Wilan KH
    Nat Biotechnol; 2005 Feb; 23(2):175-9. PubMed ID: 15696143
    [No Abstract]   [Full Text] [Related]  

  • 13. How the street sees biotech.
    Lashinsky A
    Fortune; 2003 Jun; 147(11):86. PubMed ID: 12800576
    [No Abstract]   [Full Text] [Related]  

  • 14. Little biotech on the prairie.
    Wolfson W
    Chem Biol; 2007 Sep; 14(9):969-71. PubMed ID: 17884626
    [No Abstract]   [Full Text] [Related]  

  • 15. Early-stage returns?
    Booth BL
    Nat Biotechnol; 2006 Nov; 24(11):1335-40. PubMed ID: 17093473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Market woes drag down biotech shares.
    Morrison C
    Nat Biotechnol; 2001 Nov; 19(11):995-6. PubMed ID: 11689828
    [No Abstract]   [Full Text] [Related]  

  • 17. Hwang scandal hits Korean biotech hard.
    Fuyuno I
    Nature; 2006 Jan; 439(7074):265. PubMed ID: 16421542
    [No Abstract]   [Full Text] [Related]  

  • 18. Delisting threat looms large on biotech front.
    Lawrence S
    Nat Biotechnol; 2005 Jan; 23(1):5. PubMed ID: 15637598
    [No Abstract]   [Full Text] [Related]  

  • 19. Evolving symbiosis--venture capital and biotechnology.
    Bradford TC
    Nat Biotechnol; 2003 Sep; 21(9):983-4. PubMed ID: 12949556
    [No Abstract]   [Full Text] [Related]  

  • 20. Biotech meets the investors.
    Berry S
    Trends Biotechnol; 2002 Sep; 20(9):370-1. PubMed ID: 12175762
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.